Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 828

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain

Dr Antonio González-Martín speaks to ecancer at ESMO 2019 in Barcelona about the PRIMA/ENGOT-OV26/GOG-3012 study.

He outlines the randomised, double-blind, phase 3 trial. Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive niraparib or placebo after a response to platinum-based chemotherapy.

Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation